James M. Briggs

James M. Briggs

Auto-generated profile, based on publicly available information

James M. Briggs

Department of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HCHeather A. Carlson
Heather A. Carlson
KMKevin M. Masukawa
Kevin M. Masukawa
KRKathleen Rubins
Kathleen Rubins
FBFredric D. Bushman
Fredric D. Bushman
WJWilliam L. Jorgensen
William L. Jorgensen
JMJ. Andrew McCammon
J. Andrew McCammon

1 February 2015 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJinyu Chen
Jinyu Chen
HLHo-Jeong Lee
Ho-Jeong Lee
XWXuefeng Wu
Xuefeng Wu
LHLei Huo
Lei Huo
SKSun-Jin Kim
Sun-Jin Kim
ZWZhang Weihua
Zhang Weihua
Breast cancer brain metastasis is resistant to therapy and a particularly poor prognostic feature in patient survival. Altered metabolism is a common feature of cancer cells, but little is known as to what metabolic changes benefit breast cancer brain metastases. We found that brain metastatic breast cancer cells evolved the ability to survive and proliferate independent of glucose due to enhanced gluconeogenesis and oxidations of glutamine and branched chain amino acids, which together sustain the nonoxidative pentose pathway for purine synthesis. Silencing expression of fructose-1,6-bisphosphatases (FBP) in brain metastatic cells reduced their viability and improved the survival of metastasis-bearing immunocompetent hosts. Clinically, we showed that brain metastases from human breast cancer patients expressed higher levels of FBP and glycogen than the corresponding primary tumors. Together, our findings identify a critical metabolic condition required to sustain brain metastasis and suggest that targeting gluconeogenesis may help eradicate this deadly feature in advanced breast cancer patients. Cancer Res; 75(3); 554–65. ©2014 AACR.

1 April 1997 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
TMTami J. Marrone
Tami J. Marrone
JBJames M. Briggs
James M. Briggs
JMJ. Andrew McCammon
J. Andrew McCammon
▪ Abstract Structure-based computational methods continue to enhance progress in the discovery and refinement of therapeutic agents. Several such methods and their applications are described. These include molecular visualization and molecular modeling, docking, fragment methods, 3-D database techniques, and free-energy perturbation. Related issues that are discussed include the use of simplified potential energy functions and the determination of the positions of tightly bound waters. Strengths and weaknesses of the various methods are described.

1 November 1997 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MBMaciej Baginski
Maciej Baginski
FFFederico Fogolari
Federico Fogolari
JBJames M Briggs
James M Briggs

1 September 1999 in Molecular Pharmacology
Verified
Journal Article
Closed access
ESEric D. Scheeff
Eric D. Scheeff
JBJames M. Briggs
James M. Briggs
SHStephen B. Howell
Stephen B. Howell
Intrastrand DNA adducts formed by cisplatin and oxaliplatin were modeled with molecular mechanics minimization and restrained molecular dynamics simulations in a comparative study. A reasonable set of force field parameters for the Pt atom were refined by using the available cisplatinated DNA crystal structure as a guide. This crystal structure was also used as the starting structure for the simulations. Analysis of the resulting structures indicated that the covalent effects of oxaliplatin coordination on DNA structure were very similar to those of cisplatin. The most prominent difference between the two structures resulted from the presence of the 1,2-diaminocyclohexane ring in the oxaliplatin adduct. The modeling indicated that this ring protrudes directly outward into, and fills much of, the narrowed major groove of the bound DNA, forming a markedly altered and less polar major groove in the area of the adduct. The differences in the structure of the adducts produced by cisplatin and oxaliplatin are consistent with the observation that they are differentially recognized by the DNA mismatch repair system.

1 January 2003 in Journal of Molecular Biology
Verified
Journal Article
Closed access
DLDouglas Laurents
Douglas Laurents
BHBeatrice M.P. Huyghues-Despointes
Beatrice M.P. Huyghues-Despointes
MBMarta Bruix
Marta Bruix
RTRichard L. Thurlkill
Richard L. Thurlkill
DSDavid Schell
David Schell
CPC.NIck Pace
C.NIck Pace